title: PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.
authors: Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden thomas.helleday@scilifelab.se.
authors: T
authors: T
authors: Helleday
mesh_terms: D024682:BRCA2 Protein / Q000235:genetics*; D017277:Drug Approval / Q000331:legislation & jurisprudence; D018095:Germ-Line Mutation / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008297:Male; D010793:Phthalazines / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000235:genetics*; D044767:Ubiquitin-Protein Ligases / Q000235:genetics*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
chemical_list: D024682:BRCA2 Protein; C551750:BRCA2 protein, human; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C111164:BRAP protein, human; D044767:Ubiquitin-Protein Ligases; C531550:olaparib